Broad nanovaccines to protect against diverse coronaviruses
Official title: Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites
Funded at Wistar Institute · NIH-11404994 · Data updated 2026-11-12
A research grant aims to create nanoparticle vaccines that provoke broad protection against many coronaviruses by targeting shared receptor-binding sites.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $281,893 |
| NIH project number | 5P01AI165066-03 |
| Project ID | NIH-11404994 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for coronavirus exposure or those interested in future vaccination strategies and participating in related clinical research.
✕Less likely to help
People with no access to emerging vaccines or those not eligible for vaccine trials may not directly benefit.
What this research studies
This project focuses on designing and testing nanoparticle vaccines that present conserved parts of coronavirus spike proteins to the immune system. Scientists will build a library of spike variants, use nucleic acid delivery to make these vaccines, and explore regimens that elicit antibodies targeting conserved regions. The goal is to produce vaccines that work against current and potential future coronaviruses by expanding the immune response beyond a single strain. The work will be conducted at the Wistar Institute under the leadership of Dr. Daniel Kulp.
Why it matters
Potential benefit: If successful, patients could gain protection against a broader range of coronaviruses, potentially reducing the impact of future outbreaks.
How similar studies have gone: Previous work with nanoparticle vaccines and conserved-epitope targeting has shown promise, but broad protection across diverse coronaviruses is still being established.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Kulp, Daniel — Wistar Institute
- Study coordinator: Kulp, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.